Partnering 2030: Biopharma Report 2025
The future of biopharma is being built on a foundation of collaboration between top pharma companies, innovative biotechs, and research institutes. In this report, our fourth annual deep dive into the unfiltered perspectives of biotech and academic innovators, we reveal precisely where pharma is excelling, where partnering efforts fall short, and which companies are consistently favored as partners of choice.
The Innovators Partnering Perspective
A Challenging Environment
Identifying innovation and finding new assets, therapies, platforms and technologies is the greatest challenge in biopharma today.
Industry Sentiment Down
Less than a quarter of respondents reported they were positive about the current state of the biopharma industry.
Optimistic About AI
Almost all respondents are optimistic about the impact of AI on biopharma partnering and believe it will make partnerships more efficient.
Trend in target partners for biotechs
Out licensors continue to prefer large pharma partners. Top pharma is significantly ahead of venture capital and has established a widening gap to mid-size pharma companies.